Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding

Sexually Transmitted Diseases

Volumn 36, Issue 1, 2009, Pages 11-16

  Kissinger, Patricia ^a,d   Amedee, Angela ^b   Clark, Rebecca A ^b   Dumestre, Jeanne ^b   Theall, Katherine P ^c   Myers, Leann ^a   Hagensee, Michael E ^b   Farley, Thomas A ^a   Martin, David H ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; METRONIDAZOLE; VIRUS RNA; ANTIPROTOZOAL AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; CELL FREE SYSTEM; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT DURATION; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VAGINA DISCHARGE; VIRUS CULTURE; VIRUS DETECTION; VIRUS SHEDDING; VIRUS TRANSMISSION; ANIMAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PARASITOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; UNITED STATES; VAGINA; VIROLOGY;

ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; METRONIDAZOLE; NEW ORLEANS; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS; VAGINA; VIRUS SHEDDING;

EID: 59049085210     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318186decf     Document Type: Article

References (50)

1. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-288.
2. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV- infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-843.
3. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HlV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34:1406-1411.
4. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
5. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis 2001;28(10):579-597.
6. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344:246-248.
7. Spinillo A, Debiaggi M, Zara F, et al. Factors associated with nucleic acids related to human immunodeficiency virus type 1 in cervico-vaginal secretions. BJOG 2001; 108:634-641.
8. Sorvillo F, Smith L, Kerndt P, et al. Trichomonas vaginalis, HIV, and African-Americans.[see comment]. Emerg Infect Dis 2001; 7: 927-932.
9. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601.
10. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiret- roviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
11. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervico- vaginal HIV shedding, sexually transmitted diseases and immunosup- pression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997; 11:F85-F93.
12. Al-Harthi L, Kovacs A, Coombs RW, et al. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. Aids 2001; 15:1535-1543.
13. Benki S, Mostad SB, Richardson BA, et al. Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis 2004; 189:2192-2201.
14. Fiore JR, Suligoi B, Saracino A, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. Aids 2003; 17:2169 -2176.
15. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882.
16. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997; 175:57-62.
17. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
18. Clemetson DBA, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya. JAMA 1993; 269:2860-2864.
19. Rasheed S. Infectivity and dynamics of HIV type 1 replication in the blood and reproductive tract of HIV type 1-infected women. AIDS Res Hum Retroviruses 1998; 14(suppl 1):S105-S118.
20. Debiaggi M, Zara F, Spinillo A, et al. Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001; 20:91-96.
21. Andreoletti L, Chomont N, Gresenguet G, et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital- tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis 2003; 188:549-554.
22. Seck K, Samb N, Tempesta S, et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Transm Infect 2001; 77:190-193.
23. Kovacs A, Chan LS, Chen ZC, et al. HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. J Acquir Immune Defic Syndr: JAIDS 1999; 22:124-131.
24. Mostad SB, Jackson S, Overbaugh J, et al. Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle. J Infect Dis 1998; 178:983-991.
25. Iversen AK, Fugger L, Eugen-Olsen J, et al. Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J Infect Dis 1998;178:1334-1342.
26. Goulston C, McFarland W, Katzenstein D. Human immunodeficiency virus type 1 RNA shedding in the female genital tract. J Infect Dis 1998; 177:1100 -1103.
27. Cu-Uvin S, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-sero- positive women. Obstet Gynecol 1997; 90:739 -743.
28. Henin Y, Mandelbrot L, Henrion R, et al. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr: JAIDS 1993; 6:72-75.
29. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994; 170:1597-1601.
30. Baeten JM, Mostad SB, Hughes MP, et al. Selenium deficiency is associated with shedding of HIV-1-infected cells in the female genital tract. J Acquir Immun Defic Syndr 2001;26:360-364.
31. Coombs RW, Wright DJ, Reichelderfer PS, et al. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis 2001; 184:1187-1191.
32. Cu-Uvin S, Hogan JW, Caliendo AM, et al. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 2001; 33:894-896.
33. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
34. Spinillo A, Zara F, Gardella B, et al. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. Am J Obstet Gynecol 2005; 192:774-779.
35. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-110.
36. Lawn SD, Subbarao S, Wright TC Jr, et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000; 181:1950-1956.
37. Wright TC, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001; 184:279-285.
38. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994-999.
39. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-843.
40. Kissinger P, Secor W, Leichliter J, et al. Early recurrent Trichomonas vaginalis among HIV positive and HIV negative women. Clin Infect Dis 2008; 46:994-999.
41. Mena L, Wang X, Mroczkowski TF, et al. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis 2002; 35: 1167-1173.
42. Theall KP, Clark RA, Powell A, et al. Alcohol consumption, ART usage and high-risk sex among women infected with HIV. AIDS Behav 2007; 11:205-215.
43. Zeiger S, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-130.
44. Van Der Pol B, Williams JA, Orr DP, et al. Prevalence, incidence, natural history, and response to treatment of Trichomonas vaginalis infection among adolescent women. J Infect Dis 2005; 192:2039-2044.
45. Cauci S, Culhane JF. Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and yeast. Am J Obstet Gynecol 2007; 196:133.e131-e137.
46. Benki S, Mostad SB, Richardson BA, et al. Increased levels of HIV-1-infected cells in endocervical secretions after the luteinizing hormone surge. J Acquir Immun Defic Syndr 2008; 47:529-534.
47. Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis 2007; 44(suppl 3):S102-S110.
48. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod Dec 2005; 73:1253-1263.
49. Patterson BK, Landay A, Andersson J, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998; 153:481-490.
50. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. Aids 2007; 21: 755-759.